We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Three Members of FDA’s Advisory Panel Urge Agency Reject Biogen’s Alzheimer’s Drug
Three Members of FDA’s Advisory Panel Urge Agency Reject Biogen’s Alzheimer’s Drug
Three members of an FDA advisory committee who reviewed Biogen’s investigational Alzheimer’s drug, aducanumab, have written an op-ed article in the Journal of the American Medical Association alleging an “unusual degree of collaboration” between the FDA and Biogen “potentially compromised the FDA’s objectivity” in conducting its review of the drug.